Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV + docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC]).
暂无分享,去创建一个
R. Greil | S. Barni | D. Miles | V. Müller | P. Fumoleau | D. Rayson | E. Aleknavičius | C. Wilson | E. Téllez